Biotech · Public company · Jersey City, NJ, US
Scynexis Inc
Ticker SCYX · SEC CIK 0001178253
Track this companyFree. Adds Scynexis Inc to your Dealase workspace and tells you when its record changes.
Clinical trials110 recruiting or active
Pipeline programs15From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline15
- EchinocandinPhase 3 · Candidiasis, InvasiveClinicalTrials.gov · fetched Nov 12, 2026
- FluconazolePhase 3 · Candidiasis, InvasiveClinicalTrials.gov · fetched Nov 12, 2026
- Fluconazole TabletPhase 3 · Recurrent Vulvovaginal CandidiasisClinicalTrials.gov · fetched Nov 12, 2026
- IbrexafungerpPhase 3 · Invasive CandidiasisClinicalTrials.gov · fetched Nov 12, 2026
- IbrexafungerpPhase 3 · Vulvovaginal CandidiasisClinicalTrials.gov · fetched Nov 12, 2026
- IbrexafungerpPhase 3 · Candida VulvovaginitisClinicalTrials.gov · fetched Nov 12, 2026
- IBREXAFUNGERPPhase 3 · Recurrent Vulvovaginal CandidiasisClinicalTrials.gov · fetched Nov 12, 2026
- SCY-078Phase 3 · Candidiasis, InvasiveClinicalTrials.gov · fetched Nov 12, 2026
- FluconazolePhase 2 · Candida VulvovaginitisClinicalTrials.gov · fetched Nov 12, 2026
- FluconazolePhase 2 · MycosesClinicalTrials.gov · fetched Nov 12, 2026
- MicafunginPhase 2 · MycosesClinicalTrials.gov · fetched Nov 12, 2026
- SCY-078Phase 2 · Candida VulvovaginitisClinicalTrials.gov · fetched Nov 12, 2026
- SCY-078Phase 2 · Invasive Pulmonary AspergillosisClinicalTrials.gov · fetched Nov 12, 2026
- SCY-078Phase 2 · MycosesClinicalTrials.gov · fetched Nov 12, 2026
- VoriconazolePhase 2 · Invasive Pulmonary AspergillosisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- Pharmacokinetic Study in Healthy Lactating Women Exposed to IbrexafungerpPHASE1 · COMPLETED · started Jul 12, 2023ClinicalTrials.gov NCT06954493 · fetched Nov 12, 2026
- A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral FluconazolePHASE3 · TERMINATED · started Aug 3, 2022ClinicalTrials.gov NCT05178862 · fetched Nov 12, 2026
- Ibrexafungerp for the Treatment of Complicated Vulvovaginal CandidiasisPHASE3 · COMPLETED · started May 1, 2022ClinicalTrials.gov NCT05399641 · fetched Nov 12, 2026
- Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)PHASE3 · COMPLETED · started Oct 21, 2019ClinicalTrials.gov NCT04029116 · fetched Nov 12, 2026
- Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal CandidiasisPHASE3 · COMPLETED · started Jun 7, 2019ClinicalTrials.gov NCT03987620 · fetched Nov 12, 2026
- Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary AspergillosisPHASE2 · TERMINATED · started Jan 22, 2019ClinicalTrials.gov NCT03672292 · fetched Nov 12, 2026
- Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)PHASE3 · COMPLETED · started Jan 4, 2019ClinicalTrials.gov NCT03734991 · fetched Nov 12, 2026
- Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)PHASE3 · COMPLETED · started Nov 15, 2017ClinicalTrials.gov NCT03363841 · fetched Nov 12, 2026
- Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal CandidiasisPHASE2 · COMPLETED · started Aug 1, 2017ClinicalTrials.gov NCT03253094 · fetched Nov 12, 2026
- Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal TreatmentPHASE3 · COMPLETED · started Apr 1, 2017ClinicalTrials.gov NCT03059992 · fetched Nov 12, 2026
- Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive CandidiasisPHASE2 · COMPLETED · started Sep 1, 2014ClinicalTrials.gov NCT02244606 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 28, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 10, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 26, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 22, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026